MX2023010926A - Novedoso conjugado de analogo de il-2 inmunoestimulante y procedimiento de preparacion del mismo. - Google Patents
Novedoso conjugado de analogo de il-2 inmunoestimulante y procedimiento de preparacion del mismo.Info
- Publication number
- MX2023010926A MX2023010926A MX2023010926A MX2023010926A MX2023010926A MX 2023010926 A MX2023010926 A MX 2023010926A MX 2023010926 A MX2023010926 A MX 2023010926A MX 2023010926 A MX2023010926 A MX 2023010926A MX 2023010926 A MX2023010926 A MX 2023010926A
- Authority
- MX
- Mexico
- Prior art keywords
- interleukin
- immunoactive
- novel
- preparing same
- analog conjugate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20210042305 | 2021-03-31 | ||
| PCT/KR2022/004620 WO2022211537A1 (ko) | 2021-03-31 | 2022-03-31 | 신규한 면역 활성 인터루킨 2 아날로그 결합체 및 이의 제조 방법 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023010926A true MX2023010926A (es) | 2023-09-27 |
Family
ID=83459706
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023010926A MX2023010926A (es) | 2021-03-31 | 2022-03-31 | Novedoso conjugado de analogo de il-2 inmunoestimulante y procedimiento de preparacion del mismo. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US12599675B2 (https=) |
| EP (1) | EP4316528A4 (https=) |
| JP (1) | JP2024512418A (https=) |
| KR (2) | KR102680146B1 (https=) |
| CN (1) | CN116916969A (https=) |
| AR (1) | AR125263A1 (https=) |
| AU (1) | AU2022209248B2 (https=) |
| BR (1) | BR112023018530A2 (https=) |
| CA (1) | CA3205058C (https=) |
| CL (1) | CL2023002504A1 (https=) |
| IL (1) | IL304365B2 (https=) |
| MX (1) | MX2023010926A (https=) |
| PE (1) | PE20250672A1 (https=) |
| WO (1) | WO2022211537A1 (https=) |
| ZA (1) | ZA202307219B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022009123A1 (en) * | 2020-07-09 | 2022-01-13 | Eutilex Co., Ltd. | Il-2 variants |
| AU2023408268A1 (en) | 2022-12-23 | 2025-07-10 | Hanmi Pharm. Co., Ltd. | Formulations comprising immune stimulating IL-2 analog conjugates |
| KR20240137492A (ko) * | 2023-03-07 | 2024-09-20 | 한미약품 주식회사 | 암의 예방 또는 치료를 위한 인터루킨 2 아날로그 또는 이의 결합체 및 면역관문 억제제의 병용 요법 |
| JP2026509259A (ja) * | 2023-03-07 | 2026-03-17 | ハンミ ファーマシューティカル カンパニー リミテッド | インターロイキン２アナログ又はその結合体を含む癌予防又は治療用薬学的組成物 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| KR100507796B1 (ko) * | 2003-04-03 | 2005-08-17 | 한미약품 주식회사 | 생체내 반감기가 증가된 ｐｅｇ-생리활성 폴리펩티드 동종이량체 결합체 및 이의 제조방법 |
| HUE029139T2 (hu) * | 2011-02-10 | 2017-02-28 | Roche Glycart Ag | Mutáns interleukin-2 polipeptidek |
| MX385194B (es) * | 2014-02-21 | 2025-03-14 | Nektar Therapeutics India Pvt Ltd | Agonistas il-2rbeta-selectivos en combinación con un anticuerpo anti-ctla-4 o un anticuerpo anti-pd-1. |
| GB2538666A (en) | 2014-07-21 | 2016-11-23 | Delinia Inc | Molecules that selectively activate regulatory T cells for the treatment of autoimmune diseases |
| EP3943101A1 (en) | 2014-10-21 | 2022-01-26 | SciClone Pharmaceuticals International Ltd. | Treatment of cancer with immune stimulator alpha thymosin peptide |
| WO2017052329A1 (en) * | 2015-09-24 | 2017-03-30 | Hanmi Pharm. Co., Ltd. | Protein complex by use of a specific site of an immunoglobulin fragment for linkage |
| KR102687530B1 (ko) | 2016-05-04 | 2024-07-25 | 암젠 인크 | T-조절 세포의 증식을 위한 인터류킨-2 뮤테인 |
| MX386014B (es) * | 2016-08-10 | 2025-03-18 | Univ Ajou Ind Academic Coop Found | Citocina fusionada a fc heterodimérico, y composición farmacéutica que comprende la misma. |
| US11077172B2 (en) * | 2016-11-08 | 2021-08-03 | Delinia, Inc. | IL-2 variants for the treatment of psoriasis |
| US20200299349A1 (en) * | 2017-11-21 | 2020-09-24 | The Board Of Trustees Of The Leland Stanford Junior University | Partial agonists of interleukin-2 |
| WO2019185705A1 (en) * | 2018-03-28 | 2019-10-03 | Ascendis Pharma A/S | Il-2 conjugates |
| MX2021000801A (es) * | 2018-07-24 | 2021-04-12 | BioNTech SE | Agonistas de il2. |
| WO2020057646A1 (zh) * | 2018-09-21 | 2020-03-26 | 信达生物制药(苏州)有限公司 | 新型白介素2及其用途 |
| US20220025007A1 (en) * | 2018-12-21 | 2022-01-27 | Hanmi Pharm. Co., Ltd. | Novel immunosuppressive interleukin 2 |
| TW202115105A (zh) | 2019-06-24 | 2021-04-16 | 德商拜恩迪克Ｒｎａ製藥有限公司 | Ｉｌ２激動劑 |
| KR20220044534A (ko) * | 2019-08-13 | 2022-04-08 | 엘피스 바이오파마슈티컬즈 | 조작된 인터류킨-2 수용체 베타 효능제 |
-
2022
- 2022-03-30 IL IL304365A patent/IL304365B2/en unknown
- 2022-03-31 EP EP22781656.8A patent/EP4316528A4/en active Pending
- 2022-03-31 BR BR112023018530A patent/BR112023018530A2/pt unknown
- 2022-03-31 AU AU2022209248A patent/AU2022209248B2/en active Active
- 2022-03-31 AR ARP220100795A patent/AR125263A1/es unknown
- 2022-03-31 KR KR1020220040626A patent/KR102680146B1/ko active Active
- 2022-03-31 US US18/000,096 patent/US12599675B2/en active Active
- 2022-03-31 PE PE2023002484A patent/PE20250672A1/es unknown
- 2022-03-31 MX MX2023010926A patent/MX2023010926A/es unknown
- 2022-03-31 WO PCT/KR2022/004620 patent/WO2022211537A1/ko not_active Ceased
- 2022-03-31 CN CN202280017977.7A patent/CN116916969A/zh active Pending
- 2022-03-31 JP JP2023555563A patent/JP2024512418A/ja active Pending
- 2022-03-31 CA CA3205058A patent/CA3205058C/en active Active
-
2023
- 2023-07-19 ZA ZA2023/07219A patent/ZA202307219B/en unknown
- 2023-08-24 CL CL2023002504A patent/CL2023002504A1/es unknown
-
2024
- 2024-06-14 KR KR1020240077657A patent/KR20240099117A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3205058C (en) | 2024-04-09 |
| ZA202307219B (en) | 2024-10-30 |
| PE20250672A1 (es) | 2025-03-04 |
| KR20240099117A (ko) | 2024-06-28 |
| EP4316528A4 (en) | 2026-03-11 |
| CA3205058A1 (en) | 2022-10-26 |
| AU2022209248B2 (en) | 2023-06-29 |
| CN116916969A (zh) | 2023-10-20 |
| US20240009317A1 (en) | 2024-01-11 |
| AR125263A1 (es) | 2023-06-28 |
| EP4316528A1 (en) | 2024-02-07 |
| CL2023002504A1 (es) | 2024-01-26 |
| KR20220136285A (ko) | 2022-10-07 |
| IL304365A (en) | 2023-09-01 |
| AU2022209248A1 (en) | 2022-10-20 |
| IL304365B1 (en) | 2024-12-01 |
| IL304365B2 (en) | 2025-04-01 |
| JP2024512418A (ja) | 2024-03-19 |
| KR102680146B1 (ko) | 2024-07-04 |
| WO2022211537A1 (ko) | 2022-10-06 |
| US12599675B2 (en) | 2026-04-14 |
| BR112023018530A2 (pt) | 2023-10-10 |
| TW202304521A (zh) | 2023-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023010926A (es) | Novedoso conjugado de analogo de il-2 inmunoestimulante y procedimiento de preparacion del mismo. | |
| NZ793819A (en) | Novel immunoactive interleukin 2 analog | |
| CR20240074A (es) | Anticuerpos anti-receptor de quimiocinas de motivo c-c 8 (ccr8) y métodos de uso | |
| MX2023004349A (es) | Anticuerpos monoclonales anti-ccr8 y sus usos. | |
| ZA202406384B (en) | Antibody against her3, conjugate and use thereof | |
| NL971029I1 (nl) | Bereiding van stammen van Bacillus thuringiensis met een verbeterde activiteit tegen bepaalde schubvleugelige plagen en daardoor voortgebrachte nieuwestammen. | |
| EP4385573A3 (en) | Interleukin-2 muteins for the expansion of t-regulatory cells | |
| Erard et al. | Characterization of soluble factors that induce the cytolytic activity and the expression of T cell growth factor receptors of a T cell hybrid. | |
| MX2023011241A (es) | Compuestos dirigidos a receptores de hormonas nucleares contra el cancer. | |
| WO2022162518A3 (en) | Psma binding proteins and uses thereof | |
| WO2021161287A3 (en) | Engineered anti-il-2 antibodies | |
| MX2023001504A (es) | Compuestos como inhibidores del receptor del componente complemento 5a (c5ar). | |
| WO2023039107A3 (en) | Phospho-tau antibodies and methods of use | |
| RU1838323C (ru) | Способ получени бензопиранон- @ -Д-тиоксилозидов | |
| MX2023009950A (es) | Anticuerpos que se unen a cd123 y receptores de linfocitos t gamma-delta. | |
| PH31669A (en) | Bcrf1 proteins as inhibitors of interferon-gamma. | |
| MX2024006729A (es) | Variantes de il10 y usos de las mismas. | |
| ATE260875T1 (de) | Neue, auf urethane basierende acrylcopolymer- mittel zur verbesserung der handhabung von hydraulischen bindemitteln und verfahren zu deren herstellung | |
| MX2023002778A (es) | Forma compuesta de tetraacetilendiamina. | |
| EP4482868A4 (en) | STABLE FORMULATIONS OF A MULTIVALENT, VHH-BASED, CYTOTOXIC, T-LYMPHOCYTE-ASSOCIATED ANTIGEN 4 (CTLA4) BINDING TO HUMANE CTLA4, AND METHOD FOR USE THEREMISSION | |
| MX2023007629A (es) | Muteinas de il-2 para el tratamiento contra enfermedades autoinmunitarias e inflamatorias. | |
| GEAP202516254A (en) | Construction material based on a mineral binder comprising synergistically effective hydrophobisation agent combinations | |
| ES2019842A6 (es) | Procedimiento de preparacion de hormigon bituminoso con trozos de alambre. | |
| MX2023003393A (es) | Anticuerpos e inmunoconjugados del receptor 1 de folato y usos de los mismos. | |
| RU2631773C1 (ru) | Шихта для получения железных спеченных изделий |